WED-152 Design and Study Population of MITIGATE: the First Multinational Randomized Controlled Clinical Trial in IgG4 Related Disease, Evaluating the Efficacy and Safety of the CD19 B Cell Depleting Agent Inebilizumab
Journal of Hepatology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined